|
To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: Nirsevimab Pre-Ordering Announcement
Date: September 5, 2024
The Maine Immunization Program (MIP) would like to provide pre-ordering details for the nirsevimab (Beyfortus) product for this 2024-2025 Respiratory Syncytial Virus (RSV) season.
MIP has received an allocation for both nirsevimab (Beyfortus) products. Due to allocation constraints, enrolled provider sites will not be able to order their full season supply at the opening of pre-ordering.
Enrolled provider sites should be able to receive all doses necessary to vaccinate their infant population throughout the duration of the respiratory season. The nirsevimab supply is expected to be significantly improved in comparison to the 2023-2024 RSV season. It is best practice for sites to order monthly in smaller increments, rather than occasional large order requests.
The following ordering constraints will be in effect for both nirsevimab products:
**All pre-orders MUST be placed separate from regular vaccine orders. Pre-orders placed with other vaccines in ImmPact will be denied.
-
Doses prioritized to enrolled birthing hospitals, similar to the 2023-2024 respiratory season
-
Doses for pediatric practices will be significantly limited and only available on a case-by-case basis (please contact:ImmunizeME.DHHS@maine.gov to inquire about doses)
-
Orders will be capped at 100 doses per order to begin the 2024-2025 respiratory season, but these ordering caps may be raised as the season progresses
All remaining nirsevimab products in the State of Maine from the 2023-2024 season have an expiration date ending in 2025. Any remaining inventory from last season should continue to be stored at appropriate temperature and used first at the start of the 2024-2025 RSV season.
|
